Company Description
Salarius Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing treatments for cancers with unmet medical need.
Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.
The company is based in Houston, Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | David Arthur |
Contact Details
Address: 2450 Holcombe Blvd., Suite X Houston, Texas 77021 United States | |
| Phone | (713) 913-5608 |
| Website | salariuspharma.com |
Stock Details
| Ticker Symbol | SLRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X404 |
| ISIN Number | US79400X4043 |
| Employer ID | 46-5087339 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David J. Arthur M.B.A. | Chief Executive Officer, President and Director |
| Mark J. Rosenblum CPA | Executive Vice President of Finance and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 424B5 | Filing |
| Jan 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jan 17, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 424B3 | Prospectus |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 27, 2024 | EFFECT | Notice of Effectiveness |